Key terms
About ENLV
Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ENLV news
Feb 15
6:26am ET
Buy Rating Affirmed for Enlivex Amid Promising Clinical Trials and Upcoming Data Readouts
Feb 07
8:13am ET
Enlivex Therapeutics issued U.S. patent covering Allocetra cells
Jan 17
8:03am ET
Enlivex Therapeutics receives IMOH regulatory authorization
Jan 05
11:01am ET
Biotech Alert: Searches spiking for these stocks today
Dec 21
6:30am ET
Analysts Are Bullish on These Healthcare Stocks: Enlivex (ENLV), Evolus (EOLS)
Dec 20
8:13am ET
Enlivex Therapeutics completes enrollment in Phase II trial of Allocetra
No recent news articles are available for ENLV
No recent press releases are available for ENLV
ENLV Financials
Key terms
Ad Feedback
ENLV Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ENLV Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range